Home | Welcome to Contract Pharma   
Last Updated Monday, December 29 2014

Print

Roche’s MabThera Launch Triggers $5M Halozyme Milestone



Published June 25, 2014
Related Searches: formulation
Roche’s MabThera SC has launched in Europe, triggering a $5 million milestone payment to Halozyme Therapeutics under the companies’ license and collaboration agreement. In addition to Herceptin SC, MabThera SC is the second subcutaneous formulation of one of Roche's oncology products to use Halozyme's Enhanze (recombinant human hyaluronidase) technology.
 
MabThera SC is approved for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. This formulation could potentially save time for patients, physicians and health care providers.


blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On